You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
A human monoclonal antibody therapy for treatment of hantavirus cardiopulmonary syndrome
SBC: CELDARA MEDICAL, LLC Topic: NIAIDPROJECT SUMMARY Rodent-borne viral outbreaks are increasing in both frequency and impact. As weather patterns evolve, rodent populations are affected and may multiply in areas where increased contact with humans results in infection. Hantaviruses, including Andes (ANDV) and Sin Nombre (SNV), are transmitted through the excreta of infected rodents and, when aerosolized, infect humans. In the Americ ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Automating Assessment of Contextualization of Care During the Clinical Encounter
SBC: Institute for Practice and Provider Performance Improvement, Inc. Topic: 600Background: Large scale studies have demonstrated that when patients struggle with life challenges that complicate their care (e.g., a lack of social support, competing responsibilities, or financial hardships), health care providers can improve health care outcomes and lower costs if they attempt to identify these “contextual factors” and address them in their care plan – a process termed ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
PARCA (a digital tool) to improve Justice and Health
SBC: Q2I, LLC Topic: NIDAPROJECT SUMMARY/ABSTRACT Nearly 4.4 million individuals are on community supervision in the United States, with the majority (about 80%) being supervised under probation.1 Justice involved persons (JIPs) have a 474% increased lifetime experience with heroin, a 303% increased use of OxyContin in the last 12 months, and a 256% increased use in pain medication in the last 12 months, compared to the g ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Motion-Resistant Background Subtraction Angiography with Deep Learning:Real-Time, Edge Hardware Implementation and Product Development
SBC: CLEARVOYA LLC Topic: NHLBICatheter Digital Subtraction Angiography (DSA) is an imaging technique that was developed in the 1980s to allow physicians to visualize blood vessels. Today, this technology is utilized for minimally-invasive interventions that treat numerous devastating pathologies, including stroke and myocardial infarction, diseases that disproportionally impact underserved minority patient populations.Catheter ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
A novel, non-antibiotic, microbiome-directed agent to prevent post-surgical infection
SBC: Covira Surgical Topic: NIAIDSUMMARY Covira Surgical, Inc. is developing CS-0003, a first-in-class, orally administered non-antibiotic therapy for preventing infections in patients undergoing gastrointestinal (GI) surgeries. Despite improved surgical procedures, broad use of antibiotics, mandated asepsis measures, and enhanced recovery programs, post-surgical infections remain a clear and present danger to patients. Surgical ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
SMALL MOLECULE THERAPEUTIC FOR ALZHEIMER'S DISEASE
SBC: SOMATOLYNK, INC. Topic: NIAAn estimated one out of eight individuals over the age of 65 has Alzheimer’s disease (AD), with a prevalence of 1-in-3 for those over age 85. There are approximately 5.8 million people in the USA with AD, with a global projection of over 150 million by 2050. There remains a lack of effective treatment to halt disease progression. Somatostatin receptor-4 (SSTR4) represents an innovative and viabl ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
BandPass: A Remote Monitoring System for Sarcopenia and Functional Decline
SBC: SYNCHROHEALTH LLC Topic: NIAPROJECT SUMMARY Clinical Need: Sarcopenia and frailty represent significant and growing clinical challenges whose rates increase with age, and place patients at risk for functional decline, institutionalization, or death. Resistance exercises are strongly recommended in this age group to promote muscle regeneration and strength and are routinely a part of evidence-based home exercise programs pres ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
An R2 non-neuroinvasive herpes simplex virus type 2 vaccine
SBC: THYREOS INC Topic: NIAIDPROJECT SUMMARY There is an unmet need for a herpes simplex virus (HSV) vaccine. We propose to develop a live-attenuated HSV-2 vaccine based on our R2 technology platform. R2 vaccines show unprecedented safety and efficacy in animal models, and offer antigenicity superior to subunit/mRNA and single-round vaccine designs. R2 vaccines are also the first live-attenuated alphaherpesvirus vaccines that ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Ultrasound-coupled Electrical Impedance Tomography for Sarcopenia Assessment
SBC: RYTEK MEDICAL INC Topic: NIAPROJECT SUMMARY/ABSTRACT Clinical Need: The coming decades promise a revolution in the personalized treatment for patients with breast cancer, including approaches to minimize collateral damage of curative. However, to help facilitate this, the academic and industrial clinical research communities need improved diagnostic biomarkers to assess the presence of muscle diseases such as sarcopenia. Onc ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Implantable Microarray Probe for Real-Time Glutamate and GABA Detection
SBC: ALCORIX CO Topic: 105Project Summary This STTR proposal will focus on developing and testing a novel, first-on-the-market implantable biosensor for in vivo, real-time sensing of gamma-aminobutyric acid (GABA) and glutamate (GLU) for animal studies. GABA and GLU are neurotransmitters (NTs) that are essential for information processing and plasticity, memory, and other functions. GLU is the major excitatory NT and GABA ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health